A previous regulatory setback in the US for Kissei Pharmaceutical Co., Ltd’s female health product linzagolix has not discouraged the Japanese firm from continued development of the oral gonadotropin-releasing hormone (GnRH) antagonist and building its global presence through new alliances.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?